BLCOHealthcare · Medical Instruments & SuppliesThe 13 Wall Street analysts covering Bausch + Lomb Corp. hold a median 12-month price target of $18 — +7.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bausch + Lomb Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (43): The company has been issuing shares or taking on financing, diluting existing holders.
Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BLCO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +7.0% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $21 |
| 30 July 2026 | UBS | Maintains | Buy | $21 → $23 |
| 28 July 2026 | UBS | Initiates | Buy | $21 |
| 6 July 2026 | Evercore ISI Group | Maintains | In-Line | $16 → $17 |
| 6 July 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 30 Apr 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 6 Apr 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 23 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 19 Feb 2026 | Citigroup | Maintains | Buy | — |
| 19 Feb 2026 | Stifel | Maintains | Hold | — |
| 19 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 17 Feb 2026 | Stifel | Maintains | Hold | — |
| 5 Jan 2026 | Evercore ISI Group | Downgrade | In-Line | — |
| 2 Dec 2025 | Morgan Stanley | Upgrade | Overweight | — |
| 14 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 14 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 31 Oct 2025 | Barclays | Maintains | Equal-Weight | — |
| 31 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Oct 2025 | Evercore ISI Group | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BLCO appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 67% of US stocks
Cheaper than 75% of US stocks
Cheaper than 28% of US stocks
Higher than 50% of US stocks
Higher than 47% of US stocks
Higher than 76% of US stocks
Higher than 60% of US stocks
Higher than 26% of US stocks
Higher than 41% of US stocks
Higher than 57% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bausch + Lomb Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bausch Health Companies Inc. announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of its subsidiary Bausch + Lomb Corporation, effective August 5, 2026.
Why it matters — A BLCO watcher would care because the CEO of the parent company now sits on the subsidiary's board, aligning leadership between Bausch Health and Bausch + Lomb.
Bausch + Lomb announced changes to its Board of Directors at the request of Bausch Health Companies Inc., which holds a majority ownership position in the company. The company also reaffirmed its guidance.
Why it matters — BLCO watchers would care because board composition changes requested by the majority owner can signal governance and strategic direction, while the reaffirmed guidance provides reassurance on the company's outlook.
Bausch + Lomb Corporation held its second-quarter 2026 earnings conference call, and Seeking Alpha published the transcript of that call.
Why it matters — The earnings call transcript provides investors and analysts with a detailed record of management's commentary on BLCO's quarterly financial performance and outlook.
Bausch + Lomb reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical segments, and raised its full-year revenue and adjusted EBITDA outlook.
Why it matters — The raised outlook and margin improvement signal stronger operational performance and cash generation for the company going forward.
Bausch + Lomb reported Q2 earnings of $0.16 per share, meeting the Zacks Consensus Estimate and up from $0.07 per share in the same quarter last year.
Why it matters — The results show earnings growth year over year while meeting analyst expectations, which provides a baseline for assessing the company's performance trajectory.
The 13 Wall Street analysts covering Bausch + Lomb Corp. have a median 12-month price target of $18, with estimates ranging from $16 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering Bausch + Lomb Corp., 5 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bausch + Lomb Corp. 86 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Bausch + Lomb Corp. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +7.0% from the last close, and Ticker Nerd's factor model ranks Bausch + Lomb Corp. 86 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bausch + Lomb Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLCO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $23 over the next 12 months.
Bausch + Lomb Corp. returned +21.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Bausch + Lomb Corporation, a leading health care company, primarily focuses on eye health products. The corporation specializes in the development, manufacture, and marketing of a comprehensive range of contact lenses, lens care products, ophthalmic pharmaceuticals, and surgical devices, all designed to improve sight and enhance related health outcomes.
The most recent item we track (PRNewsWire, 6 Aug 2026): "Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board". Bausch Health Companies Inc. announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of its subsidiary Bausch + Lomb Corporation, effective August 5, 2026.
Bausch + Lomb Corporation, a leading health care company, primarily focuses on eye health products. The corporation specializes in the development, manufacture, and marketing of a comprehensive range of contact lenses, lens care products, ophthalmic pharmaceuticals, and surgical devices, all designed to improve sight and enhance related health outcomes. Bausch + Lomb plays a crucial role in the vision care industry, impacting both everyday consumers and medical professionals by providing innovative solutions for vision correction and eye health. The company's offerings cater to diverse markets, including prescription eyewear, over-the-counter eye drops, and refractive laser systems used in medical facilities. Headquartered in Rochester, New York, Bausch + Lomb's commitment to advancing eye health is evident through its extensive research and development initiatives, which continually push the boundaries of eye care technology and treatment options. Through a strategic global presence, Bausch + Lomb significantly contributes to the eye health sector, addressing the growing demand for reliable and advanced vision care products worldwide.
CEO Mr. Brenton L. Saunders J.D. · 13,000 employees · Canada · https://www.bausch.com